Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
$9.09
$5.76(73.00%)
At close: 4:00 PM EST
$9.09
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $10.94
Previous CloseN/A
Volume25.73M
Average Volume (3M)4.25M
Market Cap
$1.27B
Enterprise Value$1.22B
Total Cash (Recent Filing)$462.86M
Total Debt (Recent Filing)$186.91M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Apr 30, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding139,517,270
10 Day Avg. Volume9,369,861
30 Day Avg. Volume4,246,930
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue17.76
Enterprise Value/Gross Profit17.77
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$20.14Price Target Upside121.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$94.19M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsAnalyst notes updated VIR-5500 clinical data show clear tumor marker declines and radiologic responses at intended dose levels, indicating meaningful anti-tumor activity relative to competing therapies.
Safety And TolerabilityAnalyst highlights a favorable safety profile for VIR-5500, with low rates of severe immune-related events and no dose-limiting toxicities at planned doses, suggesting a wider therapeutic window.
Strategic Partnership And FinancingAstellas collaboration supplies substantial upfront funding, shared development costs, and a U.S. co-promotion arrangement, reducing financing pressure and execution risk for key programs.
Bears Say
Biomarker-to-clinical Conversion RiskUncertainty persists about whether prostate-specific antigen declines will convert into measurable tumor shrinkage and survival improvement, leaving questions about true clinical impact.
Competitive Landscape PressureThe T-cell engager field in prostate cancer includes established comparators with high efficacy and safety standards, raising the bar for VIR-5500 to achieve clear market differentiation.
Durability Of ResponseDurability of clinical responses remains uncertain because long-term progression and survival outcomes are not yet established, creating risk that early tumor responses may not translate into lasting benefit.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.16 and its highest was $10.94 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.27B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Apr 30, 2026 which is in 58 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Feb 23, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.491 by $0.181.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.1.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 139,517,270 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.491. Following the earnings report the stock price went up 27.725%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.14 (121.59% Upside)
$20.14 (121.59% Upside)
Blogger Sentiment
Neutral
VIR Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.8%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.08%
12-Months-Change
Fundamentals
Return on Equity
-45.73%
Trailing 12-Months
Asset Growth
-28.00%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: a strategically valuable collaboration with Astellas that provides significant upfront capital, shared development burden, and global commercialization reach, together with compelling Phase I clinical data for VIR-5500 showing dose-dependent deep PSA declines, radiographic responses (45% ORR in RECIST-evaluable at high doses), limited high-grade CRS, and encouraging durability signals. Financial discipline improved in 2025 (R&D down 10%, SG&A down 23%, net loss reduced ~16%), and the company reports a strengthened cash position and runway into Q2 2028 when incorporating recent agreements. Key risks remain: the dataset is still early and relatively small, there are isolated higher-grade safety events (including two blurred-vision treatment-related discontinuations and one early Grade 3 CRS), certain payments are subject to third-party obligations and regulatory waiting periods, and continued dose optimization and longer follow-up are needed to confirm durability and broader applicability. Overall, the positives (deal, clinical signal, safety profile, financial improvements) substantially outweigh the current lowlights, though execution and maturation of data remain critical.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$20.14
▲(121.59% Upside)
Technical Analysis
Ownership Overview
14.86% Insiders
14.15% Mutual Funds
10.12% Other Institutional Investors
40.52% Public Companies and
Individual Investors